Bioinformatics company Chunlab and Boryung Biopharma have agreed to launch "Gut-scanning," a customized healthcare service that includes specialized medical institutions' analysis of the intestinal microbiome.
The two companies' tie-up is likely to create a synergic effect, as Chunlab has microbiome analysis technology, and Boryung Biopharma has secured a network of hospitals and clinics nationwide and actively carrying out genomic testing for medical institutions, the bioinformatics company said in a press release Monday.
|Chunlab and Boryung Biopharma signed a contract to present “Gut-scanning” for tailored healthcare service last Friday. (Chunlab)|
Gut-scanning provides tailored solutions, from disease prediction to prevention, through human and intestinal microbiome analysis, where 70 percent of human regulatory immune cells are present. It can analyze the microbiome's status in the gut to identify the risk of 25 diseases and care for health conditions before the onset.
Chunlab will provide microbiome analysis and customized solutions through the service, and Boryung will be responsible for the marketing part.
Imbalance in the gut microbiome is known to cause intestinal, metabolic, autoimmune, and neurological disorders. The innate genotype cannot be changed, but managing the microbiome by diet, life habit, and probiotics intake can help prevent and treat diseases related to intestinal microbial imbalance.
"The medical science will continue to develop from therapeutic to preventive point of view, and an era for personalized preventive medicine will come along with treatment," Chunlab CEO Chun Jong-sik said.
Boryung Biopharma CEO Kim Ki-chul said, “We also hope Chunlab's service will become a new paradigm in the healthcare field.”
<© Korea Biomedical Review, All rights reserved.>